EGFR and non-small cell lung carcinoma: A subsequent phase II, single-arm, open-label study (LUX-Lung 2) evaluating patients with NSCLC harboring EGFR mutations (exons 18 to 21) was conducted in 129 patients, 68 of whom received afatinib after first-line chemotherapy (Yang et al., 2012).